Literature DB >> 21771482

Chemoprophylaxis in malaria: drugs, evidence of efficacy and costs.

Sumadhya Deepika Fernando1, Chaturaka Rodrigo, Senaka Rajapakse.   

Abstract

This review concentrates on different aspects of malaria chemoprophylaxis, namely drug combinations, resistance, impact of malaria prevention in pregnancy and cost effectiveness. A MEDLINE search was performed for all articles with the key word 'Malaria' in the title field and 'Prophylaxis' in any field. The search was restricted to articles published in English within the last decade (1999-2009). Data sources included review articles published in core clinical journals, cohort studies, interventional studies, case control studies and cross sectional analyses. The mechanism of action, trial evidence of efficacy, side effects and geographical distribution of resistance is discussed for each prophylactic drug regimen. Impact of prophylaxis in pregnancy and the cost considerations are discussed under two separate sub topics.
Copyright © 2011 Hainan Medical College. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21771482     DOI: 10.1016/S1995-7645(11)60098-9

Source DB:  PubMed          Journal:  Asian Pac J Trop Med        ISSN: 1995-7645            Impact factor:   1.226


  9 in total

Review 1.  Primaquine in vivax malaria: an update and review on management issues.

Authors:  Deepika Fernando; Chaturaka Rodrigo; Senaka Rajapakse
Journal:  Malar J       Date:  2011-12-12       Impact factor: 2.979

2.  Chemoprophylaxis under sporozoites-lumefantrine (CPS-LMF) immunization induce protective immune responses against Plasmodium yoelii sporozoites infection in mice.

Authors:  Arif Jamal Siddiqui; Jyoti Bhardwaj; Walid Sabri Hamadou; Manish Goyal; Syed Amir Ashraf; Sadaf Jahan; Arshad Jamal; Pankaj Sharma; Manojkumar Sachidanandan; Riadh Badraoui; Mohd Adnan
Journal:  3 Biotech       Date:  2021-10-19       Impact factor: 2.406

Review 3.  Compliance with Primary Malaria Chemoprophylaxis: Is Weekly Prophylaxis Better Than Daily Prophylaxis?

Authors:  Chaturaka Rodrigo; Senaka Rajapakse; Sumadhya Deepika Fernando
Journal:  Patient Prefer Adherence       Date:  2020-11-09       Impact factor: 2.711

Review 4.  Tafenoquine for preventing relapse in people with Plasmodium vivax malaria.

Authors:  Senaka Rajapakse; Chaturaka Rodrigo; Sumadhya Deepika Fernando
Journal:  Cochrane Database Syst Rev       Date:  2015-04-29

5.  Preparation, characterization, and optimization of primaquine-loaded solid lipid nanoparticles.

Authors:  Wesley Nyaigoti Omwoyo; Bernhards Ogutu; Florence Oloo; Hulda Swai; Lonji Kalombo; Paula Melariri; Geoffrey Maroa Mahanga; Jeremiah Waweru Gathirwa
Journal:  Int J Nanomedicine       Date:  2014-08-11

6.  Low uptake of preventive interventions among malaria cases in Swaziland: towards malaria elimination.

Authors:  K Makadzange; N Dlamini; Z Zulu; S Dlamini; S Kunene; W Sikhondze; P Owiti; E Geoffroy; R Zachariah; T K Mengestu
Journal:  Public Health Action       Date:  2018-04-25

7.  A novel live-dead staining methodology to study malaria parasite viability.

Authors:  Erica M Pasini; Denise van den Ierssel; Henri J Vial; Clemens H M Kocken
Journal:  Malar J       Date:  2013-06-07       Impact factor: 2.979

8.  Tafenoquine for preventing relapse in people with Plasmodium vivax malaria.

Authors:  Chaturaka Rodrigo; Senaka Rajapakse; Deepika Fernando
Journal:  Cochrane Database Syst Rev       Date:  2020-09-06

9.  Plasmodium vivax Malaria in Pregnant Women in the Brazilian Amazon and the Risk Factors Associated with Prematurity and Low Birth Weight: A Descriptive Study.

Authors:  Camila Bôtto-Menezes; Mônica Caroline Silva Dos Santos; Janicéia Lopes Simplício; Jandira Menezes de Medeiros; Kelly Cristina Barroso Gomes; Isabel Cristina de Carvalho Costa; Eva Batista-Silva; Cristiana Teixeira do Nascimento; Eda Cristina da Silva Chagas; José Felipe Jardim Sardinha; Franklin Simões de Santana Filho; Marianna Brock; Azucena Bardají; Flor Ernestina Martínez-Espinosa
Journal:  PLoS One       Date:  2015-12-16       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.